HIV-1 broadly neutralizing antibodies
The present application relates broadly neutralizing monoclonal antibodies directed against HIV-1. In particular, monoclonal antibodies VRC-PG04 and VRC-PG05 are disclosed.
1. An isolated or non-naturally occurring human monoclonal antibody, wherein said monoclonal antibody neutralizes an HIV-1 virus in vitro, and further wherein the monoclonal antibody is selected from the group consisting of VRC-PG-04 or VRC-PG-05.
2. A diagnostic composition comprising a labeled antibody of claim 1 , or a fragment thereof, to detect the presence of an HIV immunogen, antigen or epitope in a sample.
3. The composition of claim 2 , wherein the sample is a biological sample.
4. The composition of claim 3 , wherein the biological sample is blood, semen or vaginal fluid.
5. An isolated or non-naturally occurring VRC-PG-04 monoclonal antibody comprising a heavy chain sequence of SEQ ID NO: 6, 21 or 22 and a light chain sequence of SEQ ID NO: 14.
6. An isolated or non-naturally occurring variant of a VRC-PG-04 monoclonal antibody comprising a heavy chain sequence selected from SEQ ID NOS: 21 or 22 and a light chain sequence selected from SEQ ID NOS: 33 or 34.
7. A vector containing and expressing a nucleic acid encoding the VRC-PG-04 monoclonal antibody of claim 5 .
8. A vector containing and expressing a nucleic acid encoding the VRC-PG-04 monoclonal antibody of claim 6 .